1. Suppressed mitochondrial respiration via NOX5-mediated redox imbalance contributes to the antitumor activity of anlotinib in oral squamous cell carcinoma
    Zhexun Huang et al, 2021, Journal of Genetics and Genomics CrossRef
  2. Metformin Potentiates the Effects of Anlotinib in NSCLC via AMPK/mTOR and ROS-Mediated Signaling Pathways
    Zhongling Zhu et al, 2021, Frontiers in Pharmacology CrossRef
  3. Anlotinib-Induced Hypertension: Current Concepts and Future Prospects
    Bing Lv et al, 2021, Current Pharmaceutical Design CrossRef
  4. Levels of pretreatment blood lipids are prognostic factors in advanced NSCLC patients treated with anlotinib
    Mengqiu Tang et al, 2021, Lipids in Health and Disease CrossRef
  5. Case Report: Anlotinib Therapy in a Patient With Recurrent and Metastatic RAIR-DTC Harboring Coexistent TERT Promoter and BRAFV600E Mutations
    Yanjun Su et al, 2021, Frontiers in Oncology CrossRef
  6. Pictilisib Enhances the Antitumor Effect of Doxorubicin and Prevents Tumor-Mediated Bone Destruction by Blockade of PI3K/AKT Pathway
    Chao Liang et al, 2021, Frontiers in Oncology CrossRef
  7. Efficacy and Safety of Anti-PD-1 Plus Anlotinib in Patients With Advanced Non–Small-Cell Lung Cancer After Previous Systemic Treatment Failure—A Retrospective Study
    Peiliang Wang et al, 2021, Frontiers in Oncology CrossRef
  8. Improving Outcomes of Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma: New Data and Ongoing Trials
    Lisha Mou et al, 2021, Frontiers in Oncology CrossRef